Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Tables)

v3.21.1
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2020
Stockholders' Equity Note [Abstract]  
Schedule of warrant and stock option grants with time-based vesting
    Warrant Grants     Stock Option Grants     Restricted Stock Units  
    Number of
shares
subject to
warrants		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
options		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
restricted
stock units		     Weighted-
average
exercise
price per
share		  
Balance at December 31, 2018     236,825     $ 26.00       135,023     $ 7.70       -     $       -  
Granted     1,112,220       5.67       203,572       3.65       730,303       -  
Exercised     (11,075 )     5.51       -       -       -       -  
Cancelled/Forfeited     (26,054 )     5.51       -       -       (100,000 )     -  
Balance at December 31, 2019     1,311,916     $ 9.35       338,595     $ 5.96       630,303     $ -  
Exercisable at December 31, 2019     1,311,916     $ 9.35       226,095     $ 6.57       630,303     $ -  
      Warrant Grants       Stock Option Grants       Restricted Stock Units  
      Number of
shares
subject to
warrants		       Weighted-
average
exercise
price per
share		       Number of
shares
subject to
options		       Weighted-
average
exercise
price per
share		       Number of
shares
subject to
restricted
stock units		       Weighted-
average
exercise
price per
share		  
Balance at December 31, 2019     1,311,916     $ 9.35       338,595     $ 5.26       630,303     $ -  
Granted     146,053       4.51       -       -       2,222,984       -  
Exercised     (681,619 )     5.57       (160,291 )     4.78       (77,234 )     -  
Expired     (103,891 )     35.54       (59,916 )     10.55                  
Cancelled/Forfeited     -       -       -       -       (475,000 )     -  
Balance at December 31, 2020     672,459     $ 8.09       118,388     $ 3.25       2,301,053     $ -  
Exercisable at December 31, 2020     672,459     $ 8.09       118,388     $ 3.25       2,301,053     $ -  
Schedule of fair value of the warrants as of original issuance date
    Issuance dates    
Risk-free interest rate     1.00 – 1.69 %  
Expected dividend yield     0 %  
Expected volatility     100 %  
Term     5 years    
Fair value of common stock   $  1.51 - 2.37    
Schedule of company’s outstanding warrants and options
Warrants Outstanding    

Warrants Exercisable

  
Exercise Price Range   Number
Outstanding		     Weighted Average
Remaining
Contractual Life (in
years)		     Weighted Average
Exercise Price		     Number
Exercisable		     Weighted
Average
Exercise Price		     Intrinsic Value  
$3.80 - $141.17     672,459       3.01     $ 8.09       672,459     $ 8.09       -  
Options Outstanding    

Options Exercisable

  
Exercise Price Range     Number
Outstanding		     Weighted Average
Remaining
Contractual Life (in
years)		     Weighted Average
Exercise Price		     Number
Exercisable		     Weighted
Average
Exercise Price		     Intrinsic Value  
  $2.64 - $6.84          118,388       3.69     $ 3.25       118,388     $ 3.25       -  
Schedule of stock-based compensation expense
    For the years ended December 31,  
    2020     2019  
Stock-based compensation expense   $ 3,284,570     $ 7,482,254  
Schedule of stock-based compensation expense categorized by equity components
   

For the years ended December 31,

  
    2020     2019  
Common stock   $ 3,169,470     $ 1,575,044  
Stock option awards     -       584,280  
Transfer of common stock by founders to contractors     115,100       5,322,930  
Total   $ 3,284,570     $ 7,482,254